
    
      The investigators will perform an open-label pilot safety study (Phase I/II clinical trial)
      with a total of 20 adult (18-35 years old) subjects with recent-onset T1D. There will be four
      study cohorts, which will be recruited sequentially all to the treatment arm: five subjects
      will be given ustekinumab, 45mg subcutaneously (SC) at 0, 4, 16, 28 and 40weeks, five
      subjects will be given ustekinumab, 90mg SC at weeks 0, 4, 16, 28 and 40, five subjects will
      be given 45mg SC at weeks 0, 4 and 16 and five subjects will be given 90mg subcutaneously
      (SC) at weeks 0, 4 and 16. Recruitment and screening for the pilot study will be completed
      within the first 6 months. The follow up period is 1 year from the first dose.
    
  